ClinicalTrials.Veeva

Menu

Renal Sympathetic Denervation From the Adventitia on Resistant Hypertension(RSDARH)

H

Henan Institute of Cardiovascular Epidemiology

Status

Unknown

Conditions

Resistant Hypertension

Treatments

Device: Radiofrequency ablation instruments

Study type

Interventional

Funder types

Other

Identifiers

NCT03758196
HenanICE201802

Details and patient eligibility

About

As one of the most common chronic diseases,The adult prevalence of hypertension is approximately 26.4% at present and will rise to 29.2% by 2025.Renal sympathetic denervation from the intima of renal artery has emerged as a potential treatment for resistant hypertension. However, renal sympathetic nerve are mainly located in the adventitia,and there is no report on renal sympathetic denervation from the adventitia of renal artery.This study is a multicenter,randomized,single-blind study,and aimed to observe the safety and efficacy of radiofrequency ablation of the renal artery from the adventitia on the basis of laparoscopic techniques for patients with resistant hypertension.

Full description

This study is a multicenter,randomized,single-blind study,and aimed to observe the safety and efficacy of radiofrequency ablation of the renal artery from the adventitia on the basis of laparoscopic techniques for patients with resistant hypertension.

Enrollment

126 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

1.18 years old ≤ age ≤ 65 years old; 2.Patients with clear diagnosis of resistant hypertension prior to enrollment:On the basis of improving lifestyle, a reasonable and tolerable amount of 3 or more kinds of antihypertensive drugs (including diuretics) for more than one month, clinic SBP≥140mmHg or (and) DBP≥90mmHg, 24 hours dynamic Blood pressure monitoring SBP>130mmHg or (and) DBP>80mmHg; 3.Estimated GFR (eGFR) ≥ 60ml/min/1.73m2; 4.The patient or his legal guardian has signed the informed consent; 5.Patients who are willing and able to perform follow-up visits.

Exclusion criteria

  1. Patients with secondary hypertension caused by any known cause;
  2. pregnant or planning to be pregnant;
  3. Patients with renal artery diameter <4mm or length <20mm;
  4. Patients with renal artery abnormalities include: hemodynamic or anatomically significant stenosis (≥50%) of renal arteries on either side;renal arterial balloon angioplasty or stenting;renal involvement on either side Multiple renal arteries,and renal arteries supply <75% of the kidneys;abnormal renal artery anatomy,such as tumor expansion;
  5. Patients with cardiovascular instability factors includes:acute myocardial infarction within six months,unstable angina or cerebrovascular disease;heart valve disease with significantly altered hemodynamics;
  6. Patients with other serious organic diseases;
  7. Patients participated in other studies.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

126 participants in 2 patient groups

Renal sympathetic denervation from the adventitia
Experimental group
Description:
Renal sympathetic denervation from the adventitia of renal artery and optimized medication regimen
Treatment:
Device: Radiofrequency ablation instruments
optimized medication regimen
No Intervention group
Description:
optimized medication regimen

Trial contacts and locations

1

Loading...

Central trial contact

Yahui Liu, Bachelor; Chuanyu Gao, Dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems